Chlamydia in pregnancy (maternal chlamydial infection) poses risks to both mother and baby. Learn about diagnosing and managing chlamydia trachomatis in pregnancy, including relevant clinical documentation, medical coding, and healthcare guidelines for optimal maternal and fetal outcomes. This resource provides information for healthcare professionals on screening, treatment, and prevention of chlamydia infection during pregnancy.
Also known as
Chlamydial infection of lower genitourinary tract
Chlamydia infection in the urethra, cervix, or vagina during pregnancy.
Other specified infectious and parasitic diseases complicating pregnancy, childbirth and the puerperium
Other infections, including chlamydia, affecting pregnancy or postpartum period.
Encounter for screening for chlamydial infection
Routine chlamydia screening during pregnancy.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the chlamydia infection confirmed?
When to use each related code
| Description |
|---|
| Chlamydia infection during pregnancy. |
| Gonorrhea infection during pregnancy. |
| Inflammation of the cervix during pregnancy. |
Coding chlamydia without specifying pregnancy status can lead to inaccurate reporting and missed opportunities for targeted interventions.
Failing to document the infection site (e.g., cervix, rectum) may impact coding specificity and reimbursement.
Discrepancies between clinical notes and coded diagnoses can trigger audits and compliance issues.
Q: What are the recommended screening guidelines for chlamydia in pregnancy and how can I implement them effectively in my practice?
A: Screening for chlamydia trachomatis in pregnancy is crucial for preventing adverse maternal and neonatal outcomes. The CDC recommends routine screening for all pregnant individuals at the first prenatal visit. For pregnant individuals younger than 25 years old, and those with risk factors such as new or multiple sex partners, a repeat screening in the third trimester is also recommended. Effective implementation involves incorporating these guidelines into standard prenatal care protocols, ensuring access to reliable testing methods, and providing appropriate counseling and treatment. Explore how standardized protocols can improve adherence to screening recommendations and minimize missed cases. Consider implementing an electronic health record (EHR) reminder system to facilitate timely screening and follow-up.
Q: What are the potential adverse effects of untreated maternal chlamydial infection on both the mother and the neonate?
A: Untreated chlamydia trachomatis in pregnancy poses significant risks to both mother and neonate. Maternal complications can include postpartum endometritis, pelvic inflammatory disease, and increased susceptibility to other sexually transmitted infections. Neonatal complications include conjunctivitis, pneumonia, and, in rare cases, prematurity and low birth weight. Prompt diagnosis and treatment are essential to mitigate these risks. Learn more about the long-term implications of untreated chlamydia in pregnancy and the importance of comprehensive sexual health education for pregnant individuals.
Patient presents with concerns regarding possible chlamydia infection during pregnancy. She reports (Symptoms: e.g., asymptomatic, vaginal discharge, dysuria, abdominal pain, intermenstrual bleeding). Relevant history includes (History: e.g., gestational age, gravidity, parity, previous STIs, sexual history, recent antibiotic use). Physical examination reveals (Findings: e.g., normal pelvic exam, cervical friability, mucopurulent discharge). Given the pregnancy and potential risks of neonatal chlamydial conjunctivitis and pneumonia, chlamydia screening is indicated. Differential diagnoses include other causes of vaginal discharge such as bacterial vaginosis and candidiasis. A nucleic acid amplification test (NAAT) of a vaginal swab or urine specimen was ordered for Chlamydia trachomatis. Maternal chlamydial infection diagnosis confirmed by positive NAAT. Patient counseled on the importance of treatment for both maternal and fetal well-being, partner treatment, safe sex practices, and potential complications of untreated chlamydia in pregnancy such as preterm premature rupture of membranes (PPROM) and preterm labor. Treatment plan initiated with azithromycin 1g orally in a single dose, consistent with CDC treatment guidelines for chlamydia in pregnancy. Patient education provided on medication side effects, follow-up testing, and the importance of partner notification and treatment. Follow-up scheduled in four weeks to assess treatment response and discuss retesting. ICD-10 code A56.01 (Chlamydia trachomatis infection of the lower genitourinary tract in pregnancy) assigned. This documentation supports medical necessity for testing and treatment.